SEARCH

SEARCH BY CITATION

References

  • 1
    Global Burden of Disease Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 2029.
  • 2
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529538.
  • 3
    Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341344.
  • 4
    Hepatitis C: global prevalence (update). Wkly Epidemiol Rec 1999; 74: 425427.
  • 5
    Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 3547.
  • 6
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558567.
  • 7
    Kim WR, Ward JW, Cheever LW, Dan C, Dee L, Zola J. Transforming the current infrastructure for combating HBV and HCV infections. J Fam Pract 2010; 59( Suppl): S65S70.
  • 8
    Mitchell AE, Colvin HM, Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. HEPATOLOGY 2010; 51: 729733.
  • 9
    Peters MG, Weinbaum C, Tan L, Baine WB, Dienstag JL, Liang TJ, et al. Recommendations for prevention, screening, and diagnosis of HBV and HCV infections. J Fam Pract 2010; 59( Suppl): S29S35.
  • 10
    GBD 2005 Study. Global burden of diseases, injuries and risk factors study operations manual (final draft, January 2009). Accessed December 5, 2010 at http://www.globalburden.org
  • 11
    Flaxman AD, Vos T, Lim S, Murray CJL (Eds). Integrated Meta-Regression Framework for Descriptive Epidemiology, University of Washington: Seattle, 2013.
  • 12
    Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28: 66536657.
  • 13
    Peng RD, Dominici F, Zeger SL. Reproducible epidemiologic research. Am J Epidemiol 2006; 163: 783789.
  • 14
    Murray CJL, Lopez AD, Wang H (eds.). Mortality estimation for national populations: methods and applications. Seattle: University of Washington; 2012.
  • 15
    Kuboki M, Shinzawa H, Shao L, Ishibashi M, Yoshii E, Suzuki K, et al. A cohort study of hepatitis C virus (HCV) infection in an HCV epidemic area of Japan: age and sex-related seroprevalence of anti-HCV antibody, frequency of viremia, biochemical abnormality and histological changes. Liver 1999; 19: 8896.
  • 16
    Ishibashi M, Shinzawa H, Kuboki M, Tsuchida H, Takahashi T. Prevalence of inhabitants with anti-hepatitis C virus antibody in an area following an acute hepatitis C epidemic: age-and area-related features. J Epidemiol 1996; 6: 17.
  • 17
    Hayashi J, Kishihara Y, Yamaji K, Yoshimura E, Kawakami Y, Akazawa A, et al. Transmission of hepatitis C virus by health care workers in a rural area of Japan. Am J Gastroenterol 1995; 90: 794799.
  • 18
    Furusyo N, Hayashi J, Ariyama I, Sawayama Y, Etoh Y, Kashiwagi S. Lower hepatitis G virus infection prevalence compared to hepatitis B and C virus infection prevalences. Diges Dis Sci 2000; 45: 188195.
  • 19
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705714.
  • 20
    Farrugia A, Penrod J, Bult JM. Payment, compensation and replacement—the ethics and motivation of blood and plasma donation. Vox Sang 2010; 99: 202211.
  • 21
    Fernandez-Montoya A. Altruism and payment in blood donation. Transfus Sci 1997; 18: 379386.
  • 22
    Albeldawi M, Ruiz-Rodriguez E, Carey WD. Hepatitis C virus: prevention, screening, and interpretation of assays. Cleve Clin J Med 2010; 77: 616626.
  • 23
    Constantinescu I, Diaconu C, Grancea C, Bleontu C, Ruta SM, Cernescu C. “Trial moves rapidly on, when the judge has determined the sentence beforehand” (W. Scott: Ivanhoe, 36) or pitfalls in serosurvey of anti-hepatitis C antibody in children. Rom J Virol 1998; 49: 1121.
  • 24
    Gelman A. Multilevel (hierarchical) modeling: what it can and cannot do. Technometrics 2006; 48: 432435.
  • 25
    Wakefield J, Shaddick G. Health-exposure modeling and the ecological fallacy. Biostatistics 2006; 7: 438455.
  • 26
    Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 116.
  • 27
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. HEPATOLOGY 2000; 31: 777782.
  • 28
    Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust N Z J Public Health 2007; 31: 3035.
  • 29
    Iversen J, Wand H, Gonnermann A, Maher L. Gender differences in hepatitis C antibody prevalence and risk behaviours amongst people who inject drugs in Australia 1998-2008. Int J Drug Policy 2010; 21: 471476.
  • 30
    McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst Revs 2006: CD005546.
  • 31
    Yeung LTF, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. HEPATOLOGY 2001; 34: 223229.
  • 32
    Batash S, Khaykis I, Raicht RF, Bini EJ. High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program. Am J Gastroenterol 2008; 103: 922927.
    Direct Link:
  • 33
    Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. HEPATOLOGY 2001; 34: 809816.
  • 34
    Fu B, Tom BD, Delahooke T, Alexander GJ, Bird SM. Event-biased referral can distort estimation of hepatitis C virus progression rate to cirrhosis, and of prognostic influences. J Clin Epidemiol 2007; 60: 11401148.
  • 35
    Seeff LB. The history of the “natural history” of hepatitis C (1968-2009). Liver Int 2009; 29: 8999.